Predicting liver‐related serious adverse events in patients with primary biliary cholangitis‐related cirrhosis treated with obeticholic acid
- 26 September 2022
- journal article
- editorial
- Published by Wiley in Liver International
- Vol. 42 (11) , 2356-2359
Abstract
No abstract availableFunding Information
- Instituto de Salud Carlos III (PI21/0080)
This publication has 17 references indexed in Scilit:
- Real-world experience with obeticholic acid in patients with primary biliary cholangitisJHEP Reports, 2021
- A simple, step-by-step guide to interpreting decision curve analysisDiagnostic and Prognostic Research, 2019
- Additional fibrate treatment in UDCA‐refractory PBC patientsLiver International, 2019
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension studyThe Lancet Gastroenterology & Hepatology, 2019
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisNew England Journal of Medicine, 2018
- Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCARevista Española de Enfermedades Digestivas, 2018
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisNew England Journal of Medicine, 2016
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incompleteUDCAresponse may improve outcomesAlimentary Pharmacology & Therapeutics, 2015
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006